Dr. Usman's Cardiology Notes

2026 AHA/ACC Multisociety Dyslipidemia Guidelines — Concise, High-Yield Summary 🔴 Core Concept “Lower LDL-C earlier and for longer” → reduces cumulative lifetime ASCVD risk Shift from short-term risk → lifetime risk + earlier intervention --- 🧪 1. Screening & Risk Assessment Start early Children: ~10 years (for familial hypercholesterolemia) Adults: from ≥19 years, repeat every 5 years  Use new PREVENT-ASCVD calculator Estimates 10-year + 30-year risk Treatment considered at ≥5% 10-year risk  Recognize South Asians = higher ASCVD risk  --- 🧬 2. Risk Enhancers (Expanded) Routine Lp(a) testing once in lifetime Increased emphasis on: ApoB Family history Metabolic syndrome Lp(a) → not directly treated but triggers aggressive LDL lowering  --- 🎯 3. LDL-C Targets (More Aggressive) General population: <100 mg/dL Intermediate/high risk: <70 mg/dL Established ASCVD / very high risk: <55 mg/dL  👉 Strong shift toward “treat-to-target” strategy --- 💊 4. P...

AHA 2025 Guidelines – Acute Coronary Syndrome (ACS) Management – Key Points The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes represents a major update to how clinicians diagnose and treat acute coronary syndromes, unifying previous STEMI and NSTEMI guideline documents into a single comprehensive evidence-based resource.  1. Unified ACS Guideline (STEMI + NSTEMI + UA) The 2025 guideline consolidates separate STEMI and NSTEMI guidance from 2013 and 2014 into one framework covering all presentations of ACS — unstable angina (UA), non-ST-elevation ACS (NSTE-ACS), and ST-elevation myocardial infarction (STEMI).  2. Early Evaluation and Initial Management Rapid assessment remains paramount: Immediate ECG and clinical risk stratification for patients with suspected ACS. Early initiation of appropriate antithrombotic therapy unless contraindicated.  3. Antiplatelet and Antithrombotic Therapy (DAPT) Dual antiplatelet therapy ...

2025 ACC/AHA Guideline on Treatment of Hypertension — What’s New in Management and Therapy Introduction The 2025 American College of Cardiology / American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults updates and replaces the 2017 guideline, providing clinicians with the latest evidence-based recommendations to improve outcomes in patients with hypertension.  --- 1. Goals of Treatment Target Blood Pressure • Universal goal of treatment is <130/80 mm Hg for most adults with hypertension.  • Encouragement to achieve even lower systolic targets (e.g., <120 mm Hg) in selected individuals if tolerated.  Risk-Guided Therapy • Treatment decisions incorporate individualized cardiovascular risk estimation using the PREVENT risk calculator, replacing the Pooled Cohort Equation. This tool includes social determinants and improves risk prediction.  --- 2. When to Start Treatment Lifestyle Fi...

  A cup of coffee a day may cut AF recurrence — the DECAF trial (AHA late-breaking science) A surprising randomized trial presented as late-breaking science at the American Heart Association’s Scientific Sessions 2025 — and published in JAMA — found that patients with atrial fibrillation (AF) who were instructed to drink at least one cup of caffeinated coffee daily had fewer recurrences of AF or atrial flutter than those asked to abstain from all caffeine. The finding challenges long-standing advice that people with AF should avoid caffeinated beverages.  What the DECAF trial did DECAF (Does Eliminating Coffee Avoid Fibrillation?) was a randomized clinical trial that enrolled about 200 adults who had AF (or atrial flutter) and had recently undergone cardioversion. Participants were randomized 1:1 to (a) consume at least one cup of caffeinated coffee per day for six months or (b) completely abstain from coffee and other sources of caffeine for six months. The trial ran across m...

 A cup of coffee a day may cut AF recurrence — the DECAF trial (AHA late-breaking science) A surprising randomized trial presented as late-breaking science at the American Heart Association’s Scientific Sessions 2025 — and published in JAMA — found that patients with atrial fibrillation (AF) who were instructed to drink at least one cup of caffeinated coffee daily had fewer recurrences of AF or atrial flutter than those asked to abstain from all caffeine. The finding challenges long-standing advice that people with AF should avoid caffeinated beverages.  What the DECAF trial did DECAF (Does Eliminating Coffee Avoid Fibrillation?) was a randomized clinical trial that enrolled about 200 adults who had AF (or atrial flutter) and had recently undergone cardioversion. Participants were randomized 1:1 to (a) consume at least one cup of caffeinated coffee per day for six months or (b) completely abstain from coffee and other sources of caffeine for six months. The trial ran across mu...

  Understanding ICD Indications: A Complete Guide to Life-Saving Technology Every year, sudden cardiac death claims hundreds of thousands of lives worldwide. For many at-risk patients, an implantable cardioverter defibrillator (ICD) can be the difference between life and death. But who exactly needs this device, and when is it recommended? This comprehensive guide explores the indications for ICD implantation and helps demystify this critical cardiac intervention. ## What Is an ICD? An implantable cardioverter defibrillator is a small device, about the size of a pocket watch, that's surgically placed under the skin near the collarbone. Connected to the heart via thin wires called leads, an ICD continuously monitors heart rhythm and can deliver electrical shocks to restore normal rhythm when dangerous arrhythmias occur. Think of it as a personal emergency medical team that's always on duty, ready to restart your heart if it stops beating effectively. ## The Two Main Categories: ...

  STEMI ECG Criteria and the Universal Definition of Myocardial Infarction: A Complete Guide for Clinicians Early and accurate diagnosis of acute myocardial infarction (AMI) remains the cornerstone of reducing morbidity and mortality in patients presenting with chest pain. Among all forms of acute coronary syndromes (ACS), ST-elevation myocardial infarction (STEMI) represents the most time-sensitive emergency, requiring immediate reperfusion therapy. This article provides a clinically relevant summary of the STEMI ECG criteria and the Universal Definition of Myocardial Infarction (UDMI), based on the latest consensus guidelines from the ESC, ACC, AHA, and WHF. --- 1. Understanding STEMI: Why Accurate ECG Interpretation Matters A 12-lead ECG remains the first and most critical diagnostic test when evaluating suspected myocardial infarction. STEMI is identified when there is evidence of acute coronary artery occlusion, producing transmural ischemia and characteristic ST-segment eleva...

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...